Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication

Vaccine

Volumn 33, Issue 10, 2015, Pages 1235-1242

  Guo, Jean ^a   Bolivar Wagers, Sara ^b   Srinivas, Nivedita ^a   Holubar, Marisa ^a   Maldonado, Yvonne ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Immunodeficiency; IVDPV; Oral polio vaccine; Polio eradication; Poliomyelitis

Indexed keywords

ORAL POLIOMYELITIS VACCINE; CAPSID PROTEIN; VP1 PROTEIN, POLIOVIRUS;

AGE DISTRIBUTION; CLINICAL STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE ERADICATION; ECONOMIC ASPECT; FLACCID PARALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNODEFICIENCY RELATED VACCINE POLIOVIRUS; INCIDENCE; MORTALITY; PALESTINIAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; SEROTYPE; SEX; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VIRUS SHEDDING; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; MALE; MUTATION RATE; PATHOGENICITY; VACCINATION; VIROLOGY;

CAPSID PROTEINS; DISEASE ERADICATION; FEMALE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MUTATION RATE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84922573835     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.018     Document Type: Review

References (77)

1. Liu X., Levin A., Makinen M., Day J. OPV vs IPV: past and future choice of vaccine in the global polio eradication program. Partn Health Reform Proj 2003.
2. Heymann D.L., Sutter R.W., Aylward R.B. A vision of a world without polio: the OPV cessation strategy. Biologicals 2006, 34(2):75-79.
3. Aylward B., Yamada T. The polio endgame. N Engl J Med 2011, 364(24):2273-2275.
4. Nathanson N. Eradication of poliovirus: fighting fire with fire. J Infect Dis 2011, 203(7):889-890.
5. Bhaumik S. Polio eradication: current status and challenges. J Family Med Prim Care 2012, 1(2):84-85.
6. Thompson K.M., Duintjer Tebbens R.J. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014, 13(2):221-234.
7. Duintjer Tebbens R.J., Pallansch M.A., Alexander J.P., Thompson K.M. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine 2010, 28(26):4312-4327.
8. Duintjer Tebbens R.J., Pallansch M.A., Kalkowska D.A., Wassilak S.G.F., Cochi S.L., Thompson K.M. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013, 33(4):703-749.
9. Duintjer Tebbens R.J., Pallansch M.A., Kim J.H., Burns C.C., Kew O.M., Oberste M.S., et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013, 33(4):680-702.
10. Thompson K.M., Duintjer Tebbens R.J. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012, 11(4):449-459.
11. Thompson K.M., Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Sutter R.W., Aylward R.B., et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 2008, 98(7):1322-1330.
12. Update on vaccine-derived polioviruses detected worldwide, April 2011-June 2012. Wkly Epidemiol Rec 2012, 87(38):358-368.
13. Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002, 296(5566):356-359.
14. Center for Disease Control and Prevention Circulation of a type 2 vaccine-derived poliovirus - Egypt, 1982-1993. MMWR Morb Mortal Wkly Rep 2001, 50(3):41-42. 51.
15. Center for Disease Control and Prevention Public health dispatch: poliomyelitis-Madagascar, 2002. MMWR Morb Mortal Wkly Rep 2002, 51(28):622.
16. Vaccine-derived Polioviruses (VDPV) Global Polio Eradication Initiative 2013, http://www.polioeradication.org/Polioandprevention/Thevirus/Vaccinederivedpolioviruses.aspx [accessed 12.01.13].
17. Martín J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006, 34(2):117-122.
18. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27(20):2649-2652.
19. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
20. Minor P. Emerging/disappearing viruses future issues concerning polio eradication. Virus Res 2002, 82(1-2):33-37.
21. Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Cáceres V.M., Jafari H., Cochi S.L., et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006, 26(6):1471-1505.
22. Pliaka V., Kyriakopoulou Z., Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012, 11(5):609-628.
23. Center for Disease Control and Prevention Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997, 46(28):641-643.
24. Center for Disease Control and Prevention Poliovirus infections in four unvaccinated children - Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep 2005, 54(41):1053-1055.
25. Center for Disease Control and Prevention Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep 2006, 55(40):1093-1097.
26. Center for Disease Control and Prevention Update on vaccine-derived polioviruses - worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007, 56(38):996-1001.
27. Center for Disease Control and Prevention Update on vaccine-derived polioviruses - worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep 2009, 58(36):1002-1006.
28. Center for Disease Control and Prevention Update on vaccine-derived polioviruses - worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep 2011, 60(25):846-850.
29. Vaccine-derived polioviruses - update. Wkly Epidemiol Rec 2006, 81(42):398-404.
30. Vaccine-derived polioviruses detected worldwide January 2008-June 2009. Wkly Epidemiol Rec 2009, 84(38):390-396.
31. Vaccine-derived polioviruses detected worldwide, July 2009-March 2011. Wkly Epidemiol Rec 2011, 86(27):277-288.
32. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J., et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004, 82(1):3-8.
33. Fiore L., Plebani A., Buttinelli G., Fiore S., Donati V., Marturano J., et al. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clin Immunol 2004, 111(1):98-102.
34. Sazzad H.M., Rainey J.J., Mach O., Sutter R., Diordista S., Kawser C.A., et al. The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh. Vaccine 2012, 30(36):5396-5400.
35. de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara Ba., et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 2012, 30(52):7561-7565.
36. Diamanti E., Ibrahimi B., Tafaj F., Mezini E., Dodbiba A., Dobi V., et al. Surveillance of suspected poliomyelitis in Albania, 1980-1995: suggestion of increased risk of vaccine associated poliomyelitis. Vaccine 1998, 16(9-10):940-948.
37. van de Ven A.A., Hoytema van Konijnenburg D.P., Wensing A.M., van Montfrans J.M. The role of prolonged viral gastrointestinal infections in the development of immunodeficiency-related enteropathy. Clin Rev Allergy Immunol 2012, 42(1):79-91.
38. De Palma A.M., Pürstinger G., Wimmer E., Patick A.K., Andries K., Rombaut B., et al. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008, 14(4):545-551.
39. The task force for global health. Polio Antivirals Initiative 2014, http://www.taskforce.org/our-work/programs/polio-antivirals-initiative [accessed 15.07.14].
40. Collett M.S., Hincks J.R., Oberste S. Anti-poliovirus activity of pocapavir in a human mopv1 challenge model. Presentation at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2013, [abstract nr G-996b].
41. Modlin J.F. Antiviral drugs for poliomyelitis. Presented at the Polio Eradication Symposium, Infectious Diseases (ID) Week 2013.
42. Income levels. World Bank's Annu World Dev Rep 2013, http://wdronline.worldbank.org/worldbank/a/incomelevel [accessed 15.01.13].
43. Buckley R.H. Chapter 116: Evaluation of suspected immunodeficiency. Nelson textbook of pediatrics 2012, 715-722. Elsevier/Saunders. R.E. Behrman, H.B. Jenson, B.F. Stanton (Eds.).
44. Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 2003, 188(12):1845-1852.
45. Shahmahmoodi S., Mamishi S., Aghamohammadi A., Aghazadeh N., Tabatabaie H., Gooya M.M., et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg Infect Dis 2010, 16(7):1133-1136.
46. R Core Team R: a language and environment for statistical computing 2013, http://www.r-project.org/.
47. Feigin R.D., Guggenheim M.A., Johnsen S.D. Vaccine-related paralytic poliomyelitis in an immunodeficient child. J Pediatr 1971, 79(4):642-647.
48. Lopez C., Biggar W.D., Park B.H., Good R.A. Nonparalytic poliovirus infections in patients with severe combined immunodeficiency disease. J Pediatr 1974, 84(4):497-502.
49. Saulsbury F.T., Winkelstein J.A., Davis L.E., Hsu S.H., D'Souza B.J., Gutcher G.R., et al. Combined immunodeficiency and vaccine-related poliomyelitis in a child with cartilage-hair hypoplasia. J Pediatr 1975, 86(6):868-872.
50. Davis L.E., Bodian D., Price D., Butler I.J., Vickers J.H. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N Engl J Med 1977, 297(5):241-245.
51. Wright P.F., Hatch M.H., Kasselberg A.G., Lowry S.P., Wadlington W.B., Karzon D.T. Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia. J Pediatr 1977, 91(3):408-412.
52. Gaebler J.W., Kleiman M.B., French M.L., Chastain G., Barrett C., Griffin C. Neurologic complications in oral polio vaccine recipients. J Pediatr 1986, 108(6):878-881.
53. Benabdellah A., Nimour M. Congenital immunodeficiency revealed by an acute anterior poliomyelitis. A case report. Med Trop (Mars) 2000, 60(4):363-364.
54. Cherkasova E.A., Yakovenko M.L., Rezapkin G.V., Korotkova E.A., Ivanova O.E., Eremeeva T.P., et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 2005, 79(2):1062-1070.
55. Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 2003, 84(Pt (5)):1215-1221.
56. Sutter R.W., Kew O.M., Cochi S.L., Aylward B. Poliovirus vaccine-live. Vaccines 2012, 598-645. Saunders Elsevier, Philadelphia. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
57. DeVries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J., et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011, 364(24):2316-2323.
58. Alexander J.P., Ehresmann K., Seward J., Wax G., Harriman K., Fuller S., et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009, 199(3):391-397.
59. Gumede N., Muthambi V., Schoub B.D. Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. Emerg Infect Dis 2012, 18(6):992-994.
60. Misbah S.A., Lawrence P.A., Kurtz J.B., Chapel H.M. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgrad Med J 1991, 67(785):301-303.
61. Hidalgo S., García Erro M., Cisterna D., Freire M.C. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J 2003, 22(6):570-572.
62. Polio Eradication & Endgame Strategic Plan 2013-2018. Global Polio Eradication Initiative 2013, http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/EndgameStratPlan_20130409_ENG.pdf [accessed 25.04.13].
63. World Health Organization Polio vaccines: WHO position paper, January 2014 - recommendations. Vaccine 2014, 32(33):4117-4118.
64. Moturi E.K., Porter K.A., Wassilak S.G., Tangermann R.H., Diop O.M., Burns C.C., et al. Progress toward polio eradication - Worldwide, 2013-2014. MMWR Morb Mortal Wkly Rep 2014, 63(21):468-472.
65. Center for Disease Control and Prevention Acute flaccid paralysis associated with circulating vaccine-derived poliovirus - Philippines, 2001. MMWR Morb Mortal Wkly Rep 2001, 50(40):874-875.
66. Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012, 8(4).
67. Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol 2012, 2(2):188-198.
68. Hovi T., Shulman L.M., van der Avoort H., Deshpande J., Roivainen M., De Gourville E.M. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect 2012, 140(1):1-13.
69. Černáková B., Sobotová Z., Rovný I., Bláhova Š., Roivainen M., Hovi T. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur J Clin Microbiol Infect Dis 2005, 24(6):438-439.
70. Blomqvist S., Savolainen C., Laine P., Hirttiö P., Lamminsalo E., Penttilä E., et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 2004, 78(9):4876-4883.
71. Shulman L.M., Manor Y., Handsher R., et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 2000, 38(10):3729-3734.
72. Li L., Ivanova O., Triki H. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis 2014, 210(suppl. 1):S368-S372. http://jid.oxfordjournals.org/content/210/suppl_1/S368.long.
73. Tinder P. Jeffrey Modell Foundation Announces Global Polio Surveillance Study. Vaccine News 2014, http://vaccinenewsdaily.com/medical_countermeasures/328498-jeffrey-modell-foundation-announces-global-polio-surveillance-study/3 [accessed 15.07.14].
74. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997, 130(3):378-387.
75. Sutter R.W., Prevots D.R., Cochi S.L. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr Clin North Am 2000, 47(2):287-308.
76. National Travel Health Network and Centre Polio vaccine information 2004, http://www.unidocs.co.uk/docs/travel/polio_vaccine.pdf [accessed 20.01.13].
77. Vidor E., Plotkin S.A. Poliovirus vaccine-inactivated. Vaccines 2012, 573-597. Saunders Elsevier, Philadelphia. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).